| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2022 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE | PORTLAND | OR | 97239-4256 | MULTNOMAH | USA | R44NS120360 | Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL) | 000 | 2 | NIH | 10/31/2023 | $0 |
| | 2024 | 2022 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE | PORTLAND | OR | 97239-4256 | MULTNOMAH | USA | R44NS120360 | Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL) | 001 | 2 | NIH | 8/5/2024 | $0 |
| | 2024 | 2021 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE | PORTLAND | OR | 97239-4256 | MULTNOMAH | USA | R43AG072984 | Alzheimer's Disease: simultaneous modulation of NMDAR, BACE1, APP and Fyn activity by palmitoylation-targeting CIRC825 | 000 | 1 | NIH | 4/4/2024 | $0 |
| | 2024 | 2021 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE | PORTLAND | OR | 97239-4256 | MULTNOMAH | USA | R41HD105560 | Development of a protein palmitoylation assay to monitor treatment of CLN1 Batten Disease | 000 | 1 | NIH | 6/18/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2022 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE STE 200 | PORTLAND | OR | 97239-4232 | MULTNOMAH | USA | R44NS120360 | Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL) | 000 | 2 | NIH | 1/25/2023 | $0 |
| | 2023 | 2022 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE | PORTLAND | OR | 97239-4256 | MULTNOMAH | USA | R44NS120360 | Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL) | 001 | 2 | NIH | 5/18/2023 | $0 |
| | 2023 | 2021 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE | PORTLAND | OR | 97239-4256 | MULTNOMAH | USA | R41HD105560 | Development of a protein palmitoylation assay to monitor treatment of CLN1 Batten Disease | 000 | 1 | NIH | 4/28/2023 | $0 |
| | 2023 | 2021 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE | PORTLAND | OR | 97239-4256 | MULTNOMAH | USA | R43AG072984 | Alzheimer's Disease: simultaneous modulation of NMDAR, BACE1, APP and Fyn activity by palmitoylation-targeting CIRC825 | 000 | 1 | NIH | 2/7/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,449,910 ) |
| | 2022 | 2022 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE STE 200 | PORTLAND | OR | 97239-4232 | MULTNOMAH | USA | R44NS120360 | Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL) | 002 | 2 | NIH | 7/1/2022 | $1,449,910 |
| | 2022 | 2021 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE STE 200 | PORTLAND | OR | 97239-4232 | MULTNOMAH | USA | R43AG072984 | Alzheimer's Disease: simultaneous modulation of NMDAR, BACE1, APP and Fyn activity by palmitoylation-targeting CIRC825 | 000 | 1 | NIH | 10/15/2021 | $0 |
| | 2022 | 2021 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE STE 200 | PORTLAND | OR | 97239-4232 | MULTNOMAH | USA | R44NS120360 | Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL) | 000 | 1 | NIH | 3/31/2022 | $0 |
| | 2022 | 2021 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE STE 200 | PORTLAND | OR | 97239-4232 | MULTNOMAH | USA | R44NS120360 | Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL) | 001 | 1 | NIH | 6/2/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $2,253,828 ) |
| | 2021 | 2021 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE STE 200 | PORTLAND | OR | 97239-4232 | MULTNOMAH | USA | R44NS120360 | Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL) | 000 | 1 | NIH | 9/17/2021 | $1,441,757 |
| | 2021 | 2021 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE STE 200 | PORTLAND | OR | 97239-4232 | MULTNOMAH | USA | R43AG072984 | Alzheimer's Disease: simultaneous modulation of NMDAR, BACE1, APP and Fyn activity by palmitoylation-targeting CIRC825 | 000 | 1 | NIH | 7/13/2021 | $507,284 |
| | 2021 | 2021 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE STE 200 | PORTLAND | OR | 97239-4232 | MULTNOMAH | USA | R41HD105560 | Development of a protein palmitoylation assay to monitor treatment of CLN1 Batten Disease | 000 | 1 | NIH | 9/3/2021 | $304,787 |
|
| Issue Date FY: 2019 ( Subtotal = -$96 ) |
| | 2019 | 2017 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE STE 200 | PORTLAND | OR | 97239-4232 | MULTNOMAH | USA | R43NS100233 | Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL) | 000 | 1 | NIH | 11/8/2018 | -$96 |
|
| Issue Date FY: 2017 ( Subtotal = $198,790 ) |
| | 2017 | 2017 | CIRCUMVENT PHARMACEUTICALS INC. | 4640 SW MACADAM AVE STE 200 | PORTLAND | OR | 97239-4232 | MULTNOMAH | USA | R43NS100233 | Development of N-tert-(Butyl)hydroxylamine (NtBuHA) as a therapeutic agent for treating Infantile Neuronal Ceroid Lipofuscinosis (INCL) | 000 | 1 | NIH | 2/14/2017 | $198,790 |
|
|
